

**Chamberlain University Institutional Review Board**

**500 W. Monroe Suite 1300 Chicago, IL 60661**

**Email:** [**irb@chamberlain.edu**](mailto:irb@chamberlain.edu)

**IORG0008174/ IRB00011037 FWA00021986**

**Study Closure Form**

**Forms must be completed, signed by the Principal Investigator, and submitted electronically to the IRB at** [**irb@chamberlain.edu**](mailto:irb@chamberlain.edu)

**Please close the study. I am no longer actively interacting with human subjects or collecting private information and/or data from human subjects.**

**Study Title:**

**Please provide a brief summary of the following (attach a separate sheet if needed):**

|  |  |  |
| --- | --- | --- |
| 1. | How many subjects participated, in total, during the course of this study? |  |
| 2. | How many subjects participated in this study since the last approval date? |  |
| 3. | If the study was conducted in multiple sites, please list how many subjects participated, in total, in this study for each site. (Otherwise, put “N/A”.) |  |
| 4. | If the study was conducted in multiple sites, please list how many subjects participated in this study since the last approval date for each site. (Otherwise, put “N/A”.) |  |
| 5. | Provide available demographic information of the final aggregate study sample. (If the sample was anonymous, please state this.) |  |
| 6. | How does the demographic profile of the final aggregate study sample compare with the target\* population? |  |
| 7. | Identify any unanticipated problems or adverse events associated with this study. Describe how these problems or events were addressed. (If none occurred, put “N/A”).  An *unanticipated problem*, as described by the Office of Human Research Protections (2007) is an event, experience, or outcome that meets the following:   1. Is unexpected in terms of nature, severity, or frequency based on the IRB-approved study protocol and the subject population being studied; 2. Is related or possibly related to participation in the research study; 3. And suggests that subjects or others are at a greater risk of harm (including physical, psychological, economic, or social) than was previously known or recognized.   An a*dverse event* is defined as an unfavorable medical occurrence (psychological or physical harm), including a sign, symptom, or disease, temporally associated with participation in the research, whether or not it might be related to a subject’s participation in the research study. If an adverse event meets the three criteria that define an unanticipated problem, the adverse event is also considered an unanticipated problem. |  |
| 8. | Please provide a brief summary of the outcomes of the study. | |
| **Hand-signed or Legal Electronic Signature:**        **Date**: | | |

\**Target population* refers to the entire population of which the researcher is interested in, is germane to the phenomenon of interest to a study, to which the researcher would like to generalize a study’s findings, and/ or to which a study’s findings are transferable. The target population is typically larger than the population accessible for study recruitment or the sample.